• Contact
  • About
  • ISSN 3049-9712
  • Authors and editors
NEWSLETTER SIGN UP
Bylines Cymru
Advertisement
  • Home
  • Politics & Society
    • Devolution
    • Economy
    • Education
    • Europe
    • Health
    • Housing
    • Media
    • Trade
    • Westminster
  • Arts & Culture
  • Hiraeth
  • Voices
    • Deialog | Interview
    • Editorial
    • Gwalia | History
    • Opinion
    • Poetry
  • Sports
No Result
View All Result
  • Home
  • Politics & Society
    • Devolution
    • Economy
    • Education
    • Europe
    • Health
    • Housing
    • Media
    • Trade
    • Westminster
  • Arts & Culture
  • Hiraeth
  • Voices
    • Deialog | Interview
    • Editorial
    • Gwalia | History
    • Opinion
    • Poetry
  • Sports
No Result
View All Result
Bylines Cymru
Home Politics & Society

Over-the-counter opioids: does Britain have a codeine problem?

The popular Netflix series Painkiller shows the extent and deadliness of the US opioids addiction epidemic. But is it also an issue here?

Amira Guirguis by Amira Guirguis
22-08-2023 17:38
in Politics & Society
Reading Time: 5 mins read
A A
Over-the-counter opioids

Photo by Haley Lawrence on Unsplash

Share on Bluesky

Earlier this year, the NHS announced that it had cut opioid prescriptions by almost half a million in four years. But opioids aren’t just available on prescription in the UK. They can be bought over the counter at pharmacies in the form of co-codamol – pills that contain codeine and paracetamol.

Each co-codamol pill contains a fixed amount of 500mg of paracetamol and between 8mg and 12.8mg of codeine, depending on the product. (Co-codamol with more than 12.8mg of codeine is only available on prescription).

Opioids consumption

Co-codamol is the second most dispensed painkiller in England after paracetamol – with over 15 million packs sold in 2021. In 2023, the UK was estimated to be the third largest consumer of codeine at over 28 tonnes after India and Italy (75 tonnes and 33.5 tonnes, respectively).

Codeine is considered a ‘weak opioid’ – 10mg of codeine is equal to 1mg of oral morphine. Once ingested, a liver enzyme called CYP2D6 converts codeine into morphine. However, some ethnic groups, such as people from north Africa, produce more of the CYP2D6 enzyme (so-called ultra-rapid metabolisers) and so are at greater risk of harm, even at regular doses.

Co-codamol is meant to be used to treat mild to moderate pain – such as period pain or toothache – but because it can also create a euphoric effect, it is at risk of being abused. Codeine can cause serious harm, including dizziness, confusion, difficulty breathing, and even death. These risks are especially great among ultra-rapid metabolisers, and among people who use other medications, such as benzodiazepines.

Cold-water extraction

Some people buy co-codamol to treat their craving for heroin when there are local heroin shortages. But anecdotal reports suggest that this drug may be abused by people who start taking the pills to treat pain and end up being addicted.

In theory, the paracetamol in the pills should prevent people from abusing them. A maximum single dose of paracetamol for an adult should not exceed 1,000mg (two co-codamol pills) as it can harm the liver. However, online groups share a simple method called ‘cold water extraction’ for removing the paracetamol.

Clinical toxicologists at Guys’ and St Thomas’ Hospital in London found case studies which suggest that the method is fairly effective at removing paracetamol from the pills, and a laboratory test backs this up. It is not clear how widespread this form of tampering is, but a YouTube clip (now removed) showing viewers how to perform the procedure had been watched more than half a million times.

Pharmaceutical firms have yet to come up with an adequate way to prevent this kind of tampering.

Banning over-the-counter codeine

Given the pills’ potential for abuse, at least 25 countries, including Germany, Japan, and the US have banned over-the-counter codeine sales. Australia also implemented a ban in February 2018, despite warnings that people would switch to stronger opioids.

However, researchers at the University of Sydney found that a year after the ban was implemented, there was a 51% drop in codeine overdoses overall (including high-strength codeine). And there was a 79% drop in overdoses from low-strength codeine, the type now only available on prescription.

In the UK, the drugs regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), intervened in 2009 to reduce harms from over-the-counter opioids, such as limiting pack sizes to 32 pills per pack and adding prominent warnings on packs to not take the pills for more than three days. In 2019, the MHRA conducted a review and decided against making co-codamol a prescription-only product.

While codeine-related deaths in England and Wales are fairly low, they have increased from 24 deaths in 1993 to 200 deaths in 2021 (200 deaths). It’s not clear if these deaths relate to over-the-counter codeine, prescription codeine, or illicit codeine (say, bought on the ‘dark web’). Nevertheless, if codeine-related deaths continue to rise, the government may wish to reconsider its position on over-the-counter sales of codeine.

Amira Guirguis, Swansea University. This article is republished from The Conversation under a Creative Commons license. Read the original article.

CLICK HERE TO SUPPORT THE BYLINES NETWORK CROWDFUNDER!

Tags: drugshealthpublic health
Previous Post

Making Big Tech pay for the UK news they use

Next Post

Who owns a dragon? Welsh company challenged over logo

Amira Guirguis

Amira Guirguis

Dr Amira Guirguis is a pharmacist who gained her PhD in the in-field detection of New Psychoactive Substance (NPS). She is the MPharm Programme Director at Swansea University Medical School and a Senior Fellow of the Higher Education Academy. She is the Scheduled Drugs Lead of the RPS (Royal Pharmaceutical Society) Science and Research Committee, a committee member of JPAG (Joint Pharmaceutical Analysis Group), RPS London North West, Research Strategy Implementation Group for Wales (RSIG), and a member of the RPS Medicines, Ethics and Practice advisory board. Her research interests focus on enhancing the in-field detection of NPS, training and education of healthcare professionals on NPS, and developing harm reduction interventions including establishing Drug Checking Services.

Related Posts

An older man is significantly ahead of a younger man on the scale. The difference in accumulated capital. The generation gap. Wealth inequality sparks dialogue on savings and mobility.
Economy

A generation under pressure

by John Greeves
16 September 2026
3 women and 1 man standing outside 10 Downing Street.
Politics & Society

Campaigners urge broadcasters to wake up to voting reform

by Samuel James Jackson
10 September 2026
A large sign in front of a fence.
Economy

Holyhead’s empty Brexit border post exposes the price of Brexit red tape

by Joe McDonald
8 September 2026
5 males standing outside HM treasury building.
Politics & Society

Steel, sacrifice and a 24-year fight for pension justice

by Mark Thomas
6 September 2026
Fibre optic cables in network switch.
Politics & Society

Can Wales shape the AI revolution before it reshapes Wales?

by Martha Garcia
27 August 2026 - Updated on 28 August 2026
Next Post
Animatronic dragon, Nantes

Who owns a dragon? Welsh company challenged over logo

PLEASE SUPPORT OUR CROWDFUNDER

BROWSE BY TAGS

austerity Austerity Project Brexit campaign climate change community Cost of living Covid Cymraeg democracy devolution economy education energy environment equality events general election health history identity inclusion independence international journalism mental health older people opinion party politics Plaid Cymru Poetry Sunday politics public health public services research Senedd South Wales Welsh culture Welsh Government Welsh heritage Welsh history Welsh language Welsh poetry Welsh writers Westminster
Bylines Cymru

We are a not-for-profit citizen journalism publication. Our aim is to publish well-written, fact-based articles and opinion pieces on subjects that are of interest to people in Cymru and beyond.

Bylines Cymru is a trading brand of Bylines Networks Limited which is separate to, but allied with, Byline Times.

Learn more about us

No Result
View All Result
  • About
  • Authors and editors
  • Complaints
  • Contact
  • Donate
  • Privacy
  • Network Map
  • Network RSS Feeds
  • Submission Guidelines
  • Download the Bylines Network App

© 2023-2026 Bylines Cymru. Powerful Citizen Journalism. ISSN 3049-9712

No Result
View All Result
  • Politics & Society
    • Devolution
    • Economy
    • Education
    • Health
    • Housing
    • Media
    • Trade
    • Westminster
  • Arts & Culture
  • Hiraeth
  • Voices | Lleisiau
    • Deialog | Interview
    • Editorial
    • Gwalia | History
    • Opinion
    • Poetry
  • Sports & Leisure

Newsletter sign up

CROWDFUNDER

© 2023-2026 Bylines Cymru. Powerful Citizen Journalism. ISSN 3049-9712